Azienda Unita' Sanitaria Locale Toscana Nord Ovest
- Address
- Via Aurelia 335, 55041 Camaiore, Italy
Neoplasms and Respiratory Tract Diseases
At Azienda Unita' Sanitaria Locale Toscana Nord Ovest, the UOC di Oncologia Medica is running clinical research focused mainly on lung cancer, melanoma, ovarian cancer, cervical cancer, and other solid tumors. These studies are designed to test new cancer treatments, improve treatment sequencing, and evaluate how well modern therapies work in patients with advanced or hard-to-treat disease.
- Research in non-small cell lung cancer includes studies for ALK-positive and EGFR-mutated disease, with a focus on improving treatment effectiveness and disease control.
- Trials in small cell lung cancer are exploring better strategies for patients whose disease returns after earlier therapy.
- Several projects examine immunotherapy and targeted treatment combinations for advanced solid tumor malignancies.
These efforts reflect a strong interest in advancing personalized cancer care for patients with difficult-to-treat tumors.
Cardiovascular Diseases in Cancer Care
The site also contributes to research on cardiotoxicity, especially heart complications related to breast cancer treatment. This work aims to improve patient safety by testing ways to reduce treatment-related heart damage and support longer-term care during cancer therapy.
- Studies are evaluating whether SGLT-2 inhibitors can help lower the risk of chemotherapy-induced cardiotoxicity.
- This research supports safer treatment planning for patients receiving cancer therapy with potential heart effects.
The focus on cardio-oncology shows an effort to protect heart health while maintaining effective cancer treatment.
Breast Cancer and Treatment Optimization
Clinical trials at this Italian research site also address early breast cancer and HER2-positive breast cancer, with attention to how treatments are combined and timed. The goal is to improve recurrence prevention and refine treatment strategies for women with hormone-responsive disease.
- Research is comparing sequential versus concurrent administration of chemotherapy and aromatase inhibitors to reduce the chance of cancer returning.
- Other studies are evaluating new options for patients with more advanced breast cancer after earlier treatment.
These trials aim to make breast cancer care more effective while keeping treatment plans practical for everyday clinical use.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Unita' Sanitaria Locale Toscana Nord Ovest
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Platinum-Pemetrexed Chemotherapy Plus Lorlatinib in ALK-Positive NSCLC with Extracranial Progression on Lorlatinib | Centro Di Riferimento Oncologico Di Aviano | Phase II | Recruiting | Mar 2024 | — |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 1 | Unknown | 2024-03-15 | 2024-03-15 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.